Active	Status	Sponsor type	Region	Phase	Filter
5 Active 1 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Murphy, Declan
ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study	Completed	3	300	Europe, Canada, US, RoW	89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)	Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd	Clear Cell Renal Cell Carcinoma	10/22	11/22
LuTectomy, NCT04430192: Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy	Active, not recruiting	1/2	20	RoW	177Lu-PSMA-617, 177Lu-PSMA, [177Lu]Lu-PSMA-617, Lu-PSMA	Peter MacCallum Cancer Centre, Australia, Movember Foundation, Medical Research Future Fund, Endocyte, E.J. Whitten Foundation Prostate Cancer Research Centre	Prostatic Neoplasms	12/22	08/25